Raymund Scheffrahn
Plus aucun poste en cours
Provenance du réseau au premier degré de Raymund Scheffrahn
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland.
9
| Subsidiary | Pharmaceuticals: Major | 9 |
| Public Company | Financial Conglomerates | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Raymund Scheffrahn via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| University of Basel | College/University | Director/Board Member Corporate Officer/Principal | |
| University of Zurich | College/University | Doctorate Degree Doctorate Degree | |
Priothera Ltd.
 Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | Biotechnology | Founder | |
| RA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| Duke University Medical Center | College/University | Corporate Officer/Principal | |
| The University of North Carolina at Chapel Hill | College/University | Corporate Officer/Principal | |
| UCB | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Anokion SA
 Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Medical/Nursing Services | Director/Board Member | |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Duke University
 Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Doctorate Degree | |
Inflazome Ltd.
 Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member | |
| DBV TECHNOLOGIES | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
Cingulate Therapeutics LLC
 Cingulate Therapeutics LLC Pharmaceuticals: MajorHealth Technology Cingulate Therapeutics LLC operates as a biopharmaceutical company. It focuses on the development of new products for the treatment of central nervous system and neurobiological disorders. The company was founded by Shane J. Schaffer, Patrick Joseph Gallagher, Matthew Brams, Arthur B. Sthraughn, Craig S. Gilgallon and Raul R. Silva and is headquartered in Kansas City, KS. | Pharmaceuticals: Major | Chief Executive Officer | |
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Shionogi, Inc.
 Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Vanderbilt University | College/University | Graduate Degree | |
University of Hawai'i at Hilo
 University of Hawai'i at Hilo Other Consumer ServicesConsumer Services University of Hawai'i at Hilo engages in the provision of services relating to higher education. It offers bachelor’s degrees, minors, master’s degrees, doctoral degrees, certificate programs, graduate certificate programs, and distance learning. The company was founded in 1947 and is headquartered in Hilo, HI. | College/University | Doctorate Degree | |
Millendo Therapeutics US, Inc.
 Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Universitätsspital Basel
 Universitätsspital Basel Hospital/Nursing ManagementHealth Services Universitätsspital Basel provides medical services. It offers medical facilities for the welfare, safety and recovery of patients. The company is headquartered in Basel, Switzerland. | Hospital/Nursing Management | Director/Board Member | |
| ZURICH INSURANCE GROUP LTD | Multi-Line Insurance | Comptroller/Controller/Auditor | |
| Vienna University of Economics & Business | College/University | Doctorate Degree | |
Quell Therapeutics Ltd.
 Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| KU School of Pharmacy | College/University | Doctorate Degree | |
Cingulate Works, Inc.
 Cingulate Works, Inc. Pharmaceuticals: MajorHealth Technology Cingulate Works, Inc. is a clinical stage biopharmaceutical company which operates drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. Its products designed to improve the lives of patients suffering from burdensome daily dosing regimens and suboptimal treatment outcomes. The company was founded by Shane J. Schaffer, Matthew N. Brams, Raul R. Silva & Craig Steven Gilgallon in 2013 and is headquartered in Kansas City, KS. | Pharmaceuticals: Major | Chief Executive Officer | |
| Abbisko Therapeutics Australia Pty Ltd. | Director/Board Member | ||
| COHERUS BIOSCIENCES, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Novartis Australia Pty Ltd.
 Novartis Australia Pty Ltd. BiotechnologyHealth Technology Novartis Australia Pty Ltd. engages in the marketing and wholesale of pharmaceutical products in Australia. The company is headquartered in North Ryde, Australia. | Biotechnology | Corporate Officer/Principal | |
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| The Royal College of Physicians | College/University | Corporate Officer/Principal | |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| AMGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| SPRUCE BIOSCIENCES, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| INDIVIOR PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| The University of Chicago | College/University | Doctorate Degree | |
| Nanjing University | College/University | Undergraduate Degree | |
| Wuxi Abbisko Biomedical Technology Co. Ltd. | Director/Board Member | ||
| Hoechst Marion Roussel, Inc. | Corporate Officer/Principal | ||
| Abbisko Hong Kong Ltd. | Director/Board Member | ||
| Shanghai Hansoh Biomedical Co. Ltd. | Corporate Officer/Principal | ||
| HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ABBISKO CAYMAN LIMITED | Pharmaceuticals: Major | Chief Executive Officer | |
Abbisko Therapeutics Co., Ltd.
 Abbisko Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology Abbisko Therapeutics Co., Ltd. engages in the research and development of biomedicine and biotechnology. Its business includes technology transfer, technical advisory, and technical services. The company was founded on April 12, 2016 and is headquartered in Shanghai, China. | Pharmaceuticals: Major | Chief Executive Officer | |
| Sabre Scientific Solutions | Corporate Officer/Principal | ||
| CINGULATE INC. | Pharmaceuticals: Major | Chief Executive Officer |
Statistiques
Internationale
| Etats-Unis | 29 |
| Suisse | 7 |
| Chine | 6 |
| Irlande | 3 |
| Royaume-Uni | 3 |
Sectorielle
| Health Technology | 28 |
| Consumer Services | 13 |
| Commercial Services | 3 |
| Health Services | 3 |
| Finance | 2 |
Opérationnelle
| Corporate Officer/Principal | 40 |
| Director/Board Member | 33 |
| Chief Tech/Sci/R&D Officer | 15 |
| Chairman | 12 |
| Chief Executive Officer | 11 |
Relations les plus connectées
| Insiders | |
|---|---|
| David Meek | 19 |
| Paul Herrling | 16 |
| Joan Bigorra | 13 |
| Dhavalkumar Patel | 12 |
| Barbara Kessler | 11 |
| Yao Chang Xu | 11 |
| Rosh Dias | 10 |
| Gregor Joos | 9 |
| Pharis Mohideen | 9 |
| Shane Schaffer | 8 |
- Bourse
- Insiders
- Raymund Scheffrahn
- Connexions Sociétés